Liver abscess that responded well to pazufloxacin therapy.
Pazufloxacin (PZFX), an injectable, new quinolone antibacterial drug, has strong antibacterial activity against gram-negative bacteria (which often account for liver abscess) and transfers well to liver tissue, gallbladder tissue, and bile. Therefore, it is probable that PZFX could be extremely useful for patients with liver abscess. Here, we report two cases of liver abscess that resolved with PZFX. PZFX was intravenously administered to patients who had undergone abscess drainage, at a dose level of 500 mg x 2/day. PZFX therapy thereby allowed the patients to shorten the period of hospital stay. Liver abscess has been considered as a poor-prognosis disorder, due to delay in diagnosis of the disorder and the high incidence of septicemia that subsequently occurs. However, now, appropriate antibacterial drug therapy in combination with abscess drainage successfully allows excellent prognosis of patients with liver abscess without the reduction in the activities of daily living (ADL) that accompanies hepatic artery injection.
Hamada
Yukihiro
Y
Department of Pharmacy, Kitasato University Hospital, 1-15-1 Kitasato, Sagamihara, Kanagawa 228-8555, Japan. yuki@kitasato-u.ac.jp
Imaizumi
Hiroshi
H
Kobayashi
Masahiro
M
Sunakawa
Keisuke
K
Saigenji
Katsunori
K
Yago
Kazuo
K
D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D004322:Drainage; D005260:Female; D024841:Fluoroquinolones / Q000627:therapeutic use*; D006801:Humans; D007902:Length of Stay; D008100:Liver Abscess / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010078:Oxazines / Q000627:therapeutic use*; D011379:Prognosis; D018805:Sepsis / Q000209:etiology / Q000517:prevention & control; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D010078:Oxazines; C078052:pazufloxacin